The deal offers Lexicon a cash infusion of $25 million as the company tries to broaden use of the heart failure and diabetes medication.
Vyalev’s clearance is the second victory for AbbVie in Parkinson’s this year, following an April readout for a drug acquired through its Cerevel buyout.
Prime Medicine will streamline research in a bid to focus on what its executives believe to be its most high-value programs, the company said Monday. “We’re not going to push all of these programs ...